Global Custom Market Research Reports Provider Company

phone

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 116
  • Category: Pharmaceuticals
  • Country: Global

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H1 2018, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 4, 8, 4, 2 and 7 respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Publisher Name : Global Markets Direct


Introduction
Global Markets Direct Report Coverage
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development
3SBio Inc
Amgen Inc
arGEN-X BV
Bioverativ Inc
Bristol-Myers Squibb Co
CSL Ltd
Dova Pharmaceuticals Inc
Enzene Biosciences Ltd
Fujifilm Holdings Corporation
Genosco Inc
Hansa Medical AB
Immunomedics Inc
Intas Pharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Momenta Pharmaceuticals Inc
Novartis AG
Pfizer Inc
Pharmagenesis Inc
Principia Biopharma Inc
Protalex Inc
Rigel Pharmaceuticals Inc
UCB SA
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles
avatrombopag - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIVV-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Chemotherapy Induced Thrombocytopenia and Idiopathic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eltrombopag olamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eltrombopag olamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FF-10102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GL-2045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hetrombopag Olamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLM-465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
letolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHN-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRTX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romiplostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romiplostim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romiplostim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rozanolixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKIO-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thrombopoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veltuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
Featured News & Press Releases
Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
Jan 03, 2018: Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)
Dec 04, 2017: Dova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual Meeting
Nov 16, 2017: New UCB research published in Science Translational Medicine
Nov 10, 2017: Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Oct 30, 2017: Argenx Launches Phase I Trial with Subcutaneous Formulation of ARGX-113
Oct 18, 2017: Novartis drug Revolade shows long-term disease control for chronic/persistent immune thrombocytopenia
Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP
Sep 20, 2017: Argenx Reaches 50% Enrollment in Phase 2 Clinical Trial of ARGX-113 in Immune Thrombocytopenia
Aug 30, 2017: Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference
Jun 21, 2017: Amgen To Present Data on Nplate At 22nd Congress of the European Hematology Association
Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP
Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States
Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Mar 31, 2017: argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List Of Tables

List of Tables
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bioverativ Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Co, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by CSL Ltd, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Dova Pharmaceuticals Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Enzene Biosciences Ltd, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Fujifilm Holdings Corporation, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Principia Biopharma Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by UCB SA, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H1 2018
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H1 2018



List Of Figures

List of Figures
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018



In this report, the EMEA Idiopathic Pulmonary Fibrosis market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025,

View Report

In this report, the United States Polyarticular Juvenile Idiopathic Arthritis Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the

View Report

In this report, the United States Idiopathic Pulmonary Fibrosis market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports